We don’t have any products to show here right now.
What is FlexPrime
FlexPrime is a premium daily joint support formula designed to support healthy joints, mobility, comfort, and long-term active living.
It combines two clinically studied branded ingredients - Kinexa® Joint Longevity Complex and AprèsFlex® - at the same daily amounts used in their clinical research: 200 mg Kinexa + 100 mg AprèsFlex. Together, they provide a complementary approach to joint health, pairing whole-joint structural and functional support with research focused on joint comfort and mobility.
One small scoop. Two research-backed ingredients. Everyday joint support.
Why FlexPrime is Different
Premium branded ingredients at research-aligned daily amounts.
-
Whole-joint support - Kinexa research evaluated joint structure, strength, and physical function - not just subjective comfort.
-
Comfort + mobility - AprèsFlex has multiple double-blind human trials supporting joint comfort and function, with significant improvements reported beginning at 5 days.
-
Simple daily formula - Two premium branded ingredients in one small ~300 mg serving. No oversized multi-ingredient blend.
What FlexPrime Supports
Daily joint support for staying active, comfortable, and moving well.
-
Healthy Joints - supports overall joint health for everyday movement and activity
-
Mobility - helps support comfortable, unrestricted movement
-
Flexibility - supports joint flexibility through training and daily life
-
Joint Comfort - helps maintain comfort during and after physical activity
-
Long-Term Joint Health - formulated to support healthy joint structure and function over time
The Science Behind FlexPrime
Two clinically studied ingredients.
Two complementary approaches to joint health.
KINEXA - Whole-Joint Structure, Strength & Function
Kinexa was studied at 200 mg daily for six months in a randomized, double-blind, placebo-controlled trial involving 100 adults ages 40-75. Unlike many joint studies that focus primarily on how the joint feels, this trial also used advanced MRI imaging to evaluate structural changes throughout the knee.
Reported results included:
-
24% improvement in knee strength
-
10% improvement in cartilage thickness
-
Improvements across 5 key joint structures - cartilage, menisci, ligaments, synovium, and subchondral bone
-
>26% improvement in functional capacity
-
Improvements in joint comfort, stiffness, and physical function
The study also evaluated cartilage composition, functional performance, and biomarkers related to inflammation and cartilage metabolism.
APRÈSFLEX - Joint Comfort, Mobility & Cartilage Health
AprèsFlex has been evaluated at 100 mg daily in randomized, double-blind, placebo-controlled human research.
In a 30-day study of 70 adults with knee osteoarthritis, researchers measured joint comfort and physical function using WOMAC, VAS, and Lequesne Functional Index scores. Significant improvements versus placebo were observed, with differences appearing as early as Day 5.
Longer-term research also evaluated 100 mg/day for 180 days and incorporated MRI measurements. The study reported improvements in WOMAC, VAS, functional testing, cartilage volume and thickness, and joint-space width compared with placebo.
FlexPrime is a trademark of Primed Performance LLC.
KINEXA™ and AprèsFlex® are trademarks of PLT Health Solutions-Laila Nutraceuticals LLC.